Review



primary antibodies against cd36  (Sanying Ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Sanying Ltd primary antibodies against cd36
    Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
    Primary Antibodies Against Cd36, supplied by Sanying Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against cd36/product/Sanying Ltd
    Average 86 stars, based on 1 article reviews
    primary antibodies against cd36 - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "Prognostic integration of tumor microenvironment and parthanatos-related genes in gastric cancer: a machine learning-driven risk model and immune landscape profiling"

    Article Title: Prognostic integration of tumor microenvironment and parthanatos-related genes in gastric cancer: a machine learning-driven risk model and immune landscape profiling

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2026.1636331

    Detection of protein expression and functional verification of CD36 and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
    Figure Legend Snippet: Detection of protein expression and functional verification of CD36 and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.

    Techniques Used: Expressing, Functional Assay, Immunohistochemical staining, Staining, Migration

    Correlation analysis of CD36, KIT with TME and PA. (A) Detection of IFN-γ secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (B) Detection of TNF-α secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001.**** denotes P < 0.0001. (C) Detection of IL-10 secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors.** denotes P < 0.01. *** denotes P < 0.001. (D) Immunofluorescence staining results of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (E) Immunofluorescence staining results of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (F) Differential analysis of immunofluorescence optical density of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (G) Differential analysis of the ratio of nuclear to total immunofluorescence optical density of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors.**** denotes P < 0.0001.
    Figure Legend Snippet: Correlation analysis of CD36, KIT with TME and PA. (A) Detection of IFN-γ secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (B) Detection of TNF-α secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001.**** denotes P < 0.0001. (C) Detection of IL-10 secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors.** denotes P < 0.01. *** denotes P < 0.001. (D) Immunofluorescence staining results of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (E) Immunofluorescence staining results of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (F) Differential analysis of immunofluorescence optical density of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (G) Differential analysis of the ratio of nuclear to total immunofluorescence optical density of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors.**** denotes P < 0.0001.

    Techniques Used: Immunofluorescence, Staining



    Similar Products

    primary antibodies against cd36  (Bioss)
    94
    Bioss primary antibodies against cd36
    Primary Antibodies Against Cd36, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against cd36/product/Bioss
    Average 94 stars, based on 1 article reviews
    primary antibodies against cd36 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    primary antibodies against cd36  (Sanying Ltd)
    86
    Sanying Ltd primary antibodies against cd36
    Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
    Primary Antibodies Against Cd36, supplied by Sanying Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against cd36/product/Sanying Ltd
    Average 86 stars, based on 1 article reviews
    primary antibodies against cd36 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    primary antibodies against cd36  (Proteintech)
    96
    Proteintech primary antibodies against cd36
    Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
    Primary Antibodies Against Cd36, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against cd36/product/Proteintech
    Average 96 stars, based on 1 article reviews
    primary antibodies against cd36 - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    primary antibodies against rabbit anti cd36  (Proteintech)
    96
    Proteintech primary antibodies against rabbit anti cd36
    Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
    Primary Antibodies Against Rabbit Anti Cd36, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against rabbit anti cd36/product/Proteintech
    Average 96 stars, based on 1 article reviews
    primary antibodies against rabbit anti cd36 - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    primary antibodies against cd36 sc-7309  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology primary antibodies against cd36 sc-7309
    Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
    Primary Antibodies Against Cd36 Sc 7309, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against cd36 sc-7309/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against cd36 sc-7309 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    primary antibodies against cd36  (ABclonal Biotechnology)
    90
    ABclonal Biotechnology primary antibodies against cd36
    Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
    Primary Antibodies Against Cd36, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against cd36/product/ABclonal Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against cd36 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin  (Proteintech)
    90
    Proteintech primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin
    Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
    Primary Antibodies Against Fth, Gpx4, Cd36, Scara1, Lox 1, Abca1, Abcg1, Scarb1, And β Actin, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin/product/Proteintech
    Average 90 stars, based on 1 article reviews
    primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin  (ABclonal Biotechnology)
    90
    ABclonal Biotechnology primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin
    Detection of protein expression and functional verification of <t>CD36</t> and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.
    Primary Antibodies Against Fth, Gpx4, Cd36, Scara1, Lox 1, Abca1, Abcg1, Scarb1, And β Actin, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin/product/ABclonal Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against fth, gpx4, cd36, scara1, lox-1, abca1, abcg1, scarb1, and β-actin - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Detection of protein expression and functional verification of CD36 and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.

    Journal: Frontiers in Immunology

    Article Title: Prognostic integration of tumor microenvironment and parthanatos-related genes in gastric cancer: a machine learning-driven risk model and immune landscape profiling

    doi: 10.3389/fimmu.2026.1636331

    Figure Lengend Snippet: Detection of protein expression and functional verification of CD36 and KIT. (A) Immunohistochemical staining results of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. N: Adjacent normal, T: Tumor. Brown indicates positive expression of CD36 and KIT, blue indicates cell nuclei. (B) Quantitative analysis of immunohistochemical optical density of CD36 and KIT in gastric cancer tissues and adjacent non-tumor tissues. ** denotes P < 0.01, *** denotes P < 0.001. (C) Migration status of MKN45 cells after treated with CD36 and KIT inhibitors; (D) Number of migrated MKN45 cells after treated with CD36 and KIT inhibitors * denotes P < 0.05.** denotes P < 0.01. (E) Detection of cell proliferation ability in MKN45 cells treated with CD36/KIT inhibitors * denotes P < 0.05.** denotes P < 0.01 (F) Differential analysis of cell apoptosis level in MKN45 cells treated with CD36/KIT inhibitors.*** denotes P < 0.001.

    Article Snippet: Subsequently, primary antibodies against CD36 (18836-1-AP, Sanying, China) or KIT (AF6153, Affinity, USA) were added, and the sections were incubated overnight at 4°C followed by incubation with HRP-conjugated secondary antibody (K5007, Dako, Denmark) at 37 °C for 30 minutes.

    Techniques: Expressing, Functional Assay, Immunohistochemical staining, Staining, Migration

    Correlation analysis of CD36, KIT with TME and PA. (A) Detection of IFN-γ secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (B) Detection of TNF-α secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001.**** denotes P < 0.0001. (C) Detection of IL-10 secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors.** denotes P < 0.01. *** denotes P < 0.001. (D) Immunofluorescence staining results of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (E) Immunofluorescence staining results of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (F) Differential analysis of immunofluorescence optical density of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (G) Differential analysis of the ratio of nuclear to total immunofluorescence optical density of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors.**** denotes P < 0.0001.

    Journal: Frontiers in Immunology

    Article Title: Prognostic integration of tumor microenvironment and parthanatos-related genes in gastric cancer: a machine learning-driven risk model and immune landscape profiling

    doi: 10.3389/fimmu.2026.1636331

    Figure Lengend Snippet: Correlation analysis of CD36, KIT with TME and PA. (A) Detection of IFN-γ secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (B) Detection of TNF-α secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001.**** denotes P < 0.0001. (C) Detection of IL-10 secretion level in MKN45 cells after treatment with CD36 and KIT inhibitors.** denotes P < 0.01. *** denotes P < 0.001. (D) Immunofluorescence staining results of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (E) Immunofluorescence staining results of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors. (F) Differential analysis of immunofluorescence optical density of PARP-1 in MKN45 cells after treatment with CD36 and KIT inhibitors. *** denotes P < 0.001. (G) Differential analysis of the ratio of nuclear to total immunofluorescence optical density of AIFM1 in MKN45 cells after treatment with CD36 and KIT inhibitors.**** denotes P < 0.0001.

    Article Snippet: Subsequently, primary antibodies against CD36 (18836-1-AP, Sanying, China) or KIT (AF6153, Affinity, USA) were added, and the sections were incubated overnight at 4°C followed by incubation with HRP-conjugated secondary antibody (K5007, Dako, Denmark) at 37 °C for 30 minutes.

    Techniques: Immunofluorescence, Staining